A phaseII study of irinotecan with bevacizumab as third line treatment for patients with metastatic colorectal cancer after failure to irinotecan who have progressed on bevacizumab with oxaliplatin-based chemotherapy in second line.
收藏NIAID Data Ecosystem2026-03-07 收录
下载链接：
https://www.omicsdi.org/dataset/ecrin-mdr-crc/2625303
下载链接
链接失效反馈官方服务：
资源简介：
Interventions: Irinotecan + Bevacizumab
Primary outcome(s): Progression Free Survival
Study Design: Single arm Non-randomized
创建时间：
2013-02-15
